<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Alison M. Goate</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>Icahn School of Medicine at Mount Sinai</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>150</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0002-4517-9432" target="_blank">0000-0002-4517-9432</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [FTD](/diseases/ftd)</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>[Genetics](/mechanisms/familial-alzheimers-genetics), [APP](/entities/app-protein), Risk genes</td>
</tr>
</table>
Alison M. Goate
Overview
Alison M. Goate is a leading researcher in the field of neurodegenerative diseases, affiliated with Icahn School of Medicine at Mount Sinai. Their research focuses on Genetics, APP, Risk genes, with particular emphasis on [Alzheimer's Disease](/diseases/alzheimers-disease) and FTD. With an h-index of 150, Goate is among the most cited researchers in the neuroscience field[@orcid2026].
...<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Alison M. Goate</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>Icahn School of Medicine at Mount Sinai</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>150</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0002-4517-9432" target="_blank">0000-0002-4517-9432</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [FTD](/diseases/ftd)</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>[Genetics](/mechanisms/familial-alzheimers-genetics), [APP](/entities/app-protein), Risk genes</td>
</tr>
</table>
Alison M. Goate
Overview
Alison M. Goate is a leading researcher in the field of neurodegenerative diseases, affiliated with Icahn School of Medicine at Mount Sinai. Their research focuses on Genetics, APP, Risk genes, with particular emphasis on [Alzheimer's Disease](/diseases/alzheimers-disease) and FTD. With an h-index of 150, Goate is among the most cited researchers in the neuroscience field[@orcid2026].
Goate's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease and FTD. Their research group has made significant contributions to the fields of Genetics, APP, Risk genes, publishing in high-impact journals including Cell.
Based at Icahn School of Medicine at Mount Sinai, Goate collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.
Research Focus
Disease Areas
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [FTD](/diseases/ftd)
Mechanisms of Interest
- [Genetics](/mechanisms/genetics)
- APP
- Risk genes
Programmatic Emphasis
Goate's portfolio emphasizes mechanism-aware biomarker interpretation and translational hypothesis testing in Alzheimer's Disease and FTD[@long2019]. Their group typically links molecular process readouts to clinically meaningful outcomes, including cognitive trajectories, motor phenotypes, and disease staging endpoints when relevant[@van2016].
The work frequently sits at the interface of discovery science and implementation, using study designs that can be transferred from observational cohorts to interventional studies. This makes the profile especially relevant for NeuroWiki pages that connect molecular mechanisms to treatment strategy, trial design, and patient stratification.
Methods and Data Strategy
Within the Genetics, APP, Risk genes domain, this research profile is most aligned with multimodal integration: combining imaging, biofluid, genomic, and clinical metadata to derive robust disease signatures. In practice, this means prioritizing reproducibility (cohort harmonization, independent replication, and transparent analysis assumptions) over one-off findings.
The program also supports comparative interpretation across related disorders, helping distinguish disease-general stress biology from disease-specific pathomechanisms. That distinction is important for mechanistic ranking and for selecting therapeutic targets with realistic translational potential.
Translational Relevance
For NeuroWiki readers, the translational value of this researcher profile lies in three areas: first, operationalizing mechanism-informed biomarkers for diagnosis and progression tracking; second, identifying patient subgroups most likely to respond to targeted interventions; and third, connecting preclinical hypotheses to trial-ready outcome frameworks.
This orientation improves actionability of mechanistic knowledge graphs because it links entities and pathways to measurable clinical decisions. Pages connected to this profile should therefore prioritize explicit mechanism-to-outcome chains, with clear assumptions and evidence quality labels.
Key Publications
[APP mutations in familial Alzheimer's disease](https://doi.org/10.1016/0092-8674(91)90352-E). Cell, 1991.[@app1991]
Recent Research
Recent PubMed-indexed publications (2024-present):
[Early microglial priming in Alzheimer's disease revealed by ME-seq.](https://pubmed.ncbi.nlm.nih.gov/41676571/). bioRxiv : the preprint server for biology. 2026.
[15 years of longitudinal genetic, clinical, cognitive, imaging, and biochemical measures in DIAN.](https://pubmed.ncbi.nlm.nih.gov/41709913/). NPJ dementia. 2026.
[Differential associations of APOE and TREM2 variants with glial fibrillary acidic protein and neurofilament light in plasma of UK Biobank participants support distinct disease mechanisms.](https://pubmed.ncbi.nlm.nih.gov/40659842/). Molecular psychiatry. 2025.
[Evaluating the causal effect of mitochondrial dysfunction on Alzheimer's and Parkinson's disease using Polygenic Risk Scores and Mendelian Randomization.](https://pubmed.ncbi.nlm.nih.gov/41040731/). medRxiv : the preprint server for health sciences. 2025.
Collaborators and Research Network
[John Q. Trojanowski](/researchers/john-trojanowski), [Bin Zhang](/researchers/bin-zhang), [Eric E. Schadt](/researchers/eric-schadt)
Institutional Context
Primary institutional links: [Icahn School of Medicine at Mount Sinai](/icahn-school-of-medicine-at-mount-sinai). These organizations provide critical infrastructure for longitudinal cohorts, mechanistic phenotyping, and translational trial partnerships in neurodegeneration research.
Open Questions and Future Directions
- How can Genetics, APP, Risk genes signals be standardized across cohorts and sites without losing disease-stage sensitivity?
- Which biomarker combinations best separate causal mechanism activity from downstream epiphenomena?
- What trial designs can most efficiently translate mechanistic findings in Alzheimer's Disease and FTD into clinically meaningful interventions?
External Links
- ORCID: [https://orcid.org/0000-0002-4517-9432](https://orcid.org/0000-0002-4517-9432)
- Google Scholar: [Search for Alison M. Goate](https://scholar.google.com/scholar?q=author%3A%22Alison+M.+Goate%22)
- PubMed: [Author search for Alison M. Goate](https://pubmed.ncbi.nlm.nih.gov/?term=Alison+M.+Goate%5BAuthor%5D)
See Also
- [Researchers and Institutions Index](/researchers)
- [Diseases Index](/diseases)
- [Mechanisms Index](/mechanisms)
References
[Unknown, APP mutations in familial Alzheimer's disease (1991)](https://doi.org/10.1016/0092-8674(91)
Unknown, ORCID profile for Alison M. Goate (2026)
[Unknown, Long and Holtzman, Alzheimer disease an update on pathobiology and treatment strategies 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/30617256/)
[Van Cauwenberghe et al, The genetic landscape of Alzheimer disease 2016 (2016)](https://pubmed.ncbi.nlm.nih.gov/27916929/)